Rapid and sustained response to tralokinumab in a patient with severe bullous pemphigoid and end-stage kidney disease

Clin Exp Dermatol. 2024 Jan 25;49(2):161-163. doi: 10.1093/ced/llad331.

Authors

Roberto Maglie¹, Maria Efenesia Baffa¹, Stefano Senatore¹, Carlo Pipitò¹, Marzia Caproni¹, Farzan Solimani², Emiliano Antiga¹

Affiliations

¹ Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.
² Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.

PMID: 37757836
DOI: 10.1093/ced/llad331

No abstract available

MeSH terms

Antibodies, Monoclonal / therapeutic use
Humans
Kidney Failure, Chronic* / complications
Kidney Failure, Chronic* / drug therapy
Pemphigoid, Bullous* / complications
Pemphigoid, Bullous* / drug therapy
Skin

Substances

tralokinumab
Antibodies, Monoclonal